stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Operating cash flow
Arcutis Biotherapeutics, Inc.'s operating cash flow for fiscal 2025 was −$5.6M, compared with −$112.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $60.0M. Over the past ten years it has ranged from −$257.7M (fiscal 2022) to −$3.8M (fiscal 2017); the current reading is higher than 89% of that period. Operating cash flow has risen for 3 consecutive fiscal years. Arcutis Biotherapeutics, Inc. ranks 34th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$5.6M | — |
| FY2024 | −$112.2M | — |
| FY2023 | −$247.1M | — |
| FY2022 | −$257.7M | — |
| FY2021 | −$174.6M | — |
| FY2020 | −$113.0M | — |
| FY2019 | −$42.8M | — |
| FY2018 | −$14.1M | — |
| FY2017 | −$3.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $18.9M | 49.52% |
| Jun 2026 | $12.6M | 464.49% |
| Mar 2026 | $2.2M | (91.45%) |
| Dec 2025 | $26.2M | — |
| 29 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | $60.0M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$89.4M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$158.4M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement